N-(4-methyl-3-(trifluoromethyl)phenyl)acetamide | 22957-86-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-methyl-3-(trifluoromethyl)phenyl)acetamide
• 英文别名: N-(4-methyl-3-trifluoromethyl-phenyl)-acetamide；N-(4-methyl-3-trifluoromethyl-phenyl)acetamide；5-Acetylamino-2-methyl-benzotrifluorid；N-[4-methyl-3-(trifluoromethyl)phenyl]acetamide
• CAS: 22957-86-4
• 化学式: C₁₀H₁₀F₃NO
• mdl: MFCD06253768
• 分子量: 217.191
• InChiKey: FPRARKAQGVXANU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-methyl-3-(trifluoromethyl)phenyl)acetamide 生成
  参考文献：
  名称：

  Studies on riboflavin analogs

  摘要：

  DOI：

  10.1007/bf00478402
• 作为产物：
  描述：

  四氯化碳 、 4-甲基乙酰苯胺 在 氢氟酸 、 五氟化锑 、 吡啶 作用下， 反应 0.5h， 以65%的产率得到N-(4-methyl-3-(trifluoromethyl)phenyl)acetamide
  参考文献：
  名称：

  Regioselective electrophilic trifluoromethylation of substituted anilines and derivatives in superacid

  摘要：

  In a one pot procedure, treatment of chloro or methyl substituted acetanilides in HF/SbF5/CCl4 followed by addition of HF/pyridine yields trifluoromethyl derivatives with high regioselectivity. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(03)00124-2

文献信息

• Dihydro-benzo[b][1,4]diazepin-2-one derivatives
  申请人：——

  公开号：US20030166639A1

  公开（公告）日：2003-09-04

  This invention relates to dihydro-benzo[b][1,4]diazepin-2-one derivatives of the formula 1 wherein R 1 , R 2 , X and Y are as defined in the specification and R 3 is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.

  这项发明涉及公式为1的二氢苯并[b][1,4]二氮杂二氢吡嗪-2-酮衍生物，其中R 1 ，R 2 ，X和Y如规范中所定义，R 3 是含有1至3个氮原子的六元芳香杂环或如规范中进一步定义的吡啶-N-氧化物。该发明还涉及含有这些化合物的药物、它们的制备方法以及它们用于制备治疗或预防急性和/或慢性神经系统疾病的药物。
• [EN] COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS<br/>[FR] COMBINAISON D'ANTAGONISTE MGLUR2 ET D'INHIBITEUR ACHE DESTINEE AU TRAITEMENT DE TROUBLES NEUROLOGIQUES AIGUS ET/OU CHRONIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005014002A1

  公开（公告）日：2005-02-17

  The present invention relates to a method of treatment or prevention of acute and/or chronic neurological disorders, to a pharmaceutical composition comprising an inhibitor of acetylcholinesterase (AChE inhibitor) and a metabotropic Glutamate receptor 2 antagonist (mGluR2 antagonist), to the use of an AChE inhibitor and a mGluR2 antagonist in the preparation of a medicament, and. to kits comprising an AChE inhibitor and a mGluR2 antagonist.

  本发明涉及一种治疗或预防急性和/或慢性神经系统疾病的方法，涉及一种包含乙酰胆碱酯酶抑制剂（AChE抑制剂）和代谢型谷氨酸受体2拮抗剂（mGluR2拮抗剂）的药物组合物，涉及在制备药物中使用AChE抑制剂和mGluR2拮抗剂，以及包含AChE抑制剂和mGluR2拮抗剂的试剂盒。
• Pharmaceutical composition comprising an AChE inhibitor and a mGluR2 antagonist
  申请人：Ballard Maria Theresa

  公开号：US20050049243A1

  公开（公告）日：2005-03-03

  The present invention relates to a pharmaceutical composition comprising an inhibitor of acetylcholinesterase (AChE inhibitor) and a metabotropic glutamate receptor 2 antagonist (mGluR2 antagonist) and a pharmaceutically acceptable excipient. The invention also relates to a method of treating and/or preventing acute and/or chronic neurological disorders comprising administering to a patient in need of such treatment and/or prevention a therapeutically effective amount of said AChE inhibitor and mGluR2 antagonist as well as a kit comprising said AChE inhibitor and mGluR2 antagonist. In particular, the mGluR2 antagonist relates to the compound of formula I wherein, R 1 , R 2 , R 3 , X and Y are described hereinabove. The combination of the AChE inhibitor and mGluR2 antagonist is useful for treating and/or preventing chronic neurological disorders. These disorders include Alzheimer's disease and mild cognitive impairment.

  本发明涉及一种制药组合物，包括一种乙酰胆碱酯酶抑制剂（AChE抑制剂）和一种代谢型谷氨酸受体2拮抗剂（mGluR2拮抗剂），以及一种药用可接受的辅料。本发明还涉及一种治疗和/或预防急性和/或慢性神经系统疾病的方法，包括向需要此类治疗和/或预防的患者施用所述AChE抑制剂和mGluR2拮抗剂的治疗有效量，以及包含所述AChE抑制剂和mGluR2拮抗剂的试剂盒。特别是，mGluR2拮抗剂涉及式I的化合物，其中，R1、R2、R3、X和Y如上所述。AChE抑制剂和mGluR2拮抗剂的组合对于治疗和/或预防慢性神经系统疾病是有用的。这些疾病包括阿尔茨海默病和轻度认知障碍。
• SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：US20140329836A1

  公开（公告）日：2014-11-06

  This invention provides compounds of formula (I): wherein R 1 , R 2 , G, n, p and q have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

  本发明提供了式(I)的化合物：其中R1、R2、G、n、p和q的值如规范所述，可用作HDAC6的抑制剂。本发明还提供了包含本发明化合物的制药组合物和使用该组合物治疗增生性、炎症性、感染性、神经系统或心血管疾病或障碍的方法。
• Copper-Free Direct C–H Trifluoromethylation of Acetanilides with Sodium Trifluoromethanesulfinate
  作者：Mingxi Wu、Xinfei Ji、Wenpeng Dai、Song Cao

  DOI：10.1021/jo501221h

  日期：2014.10.3

  A copper-free direct C-H ortho trifluoromethylation of electron-deficient 4-substituted acetanilides using Langlois reagent (NaSO2CF3) as the CF3 source in the presence of tert-butyl hydroperoxide (tBuOOH, TBHP) was developed.